Science
Mechanism of Action
Palmitoyl Heptapeptide-27 functions as a synthetic biomimetic lipo-peptide, actively signaling keratinocytes—the primary cells of the epidermis. This signaling pathway promotes the increased production of critical structural proteins, specifically filaggrin and loricrin. These proteins are instrumental in fortifying the skin's barrier integrity, enhancing natural moisturizing factor (NMF) synthesis, facilitating pH balance, and ultimately contributing to overall skin homeostasis.
Research
Clinical Evidence
Low confidenceN/A
Key findings
- 01 When integrated into an innovative complex (X50 Skin barrier) alongside Palmitoyl Oligopeptide-78, a study reported notable improvements. Following 28 days of consistent daily application, participants exhibited a 10% increase in epidermal thickness and a 9% reduction in transepidermal water loss (TEWL).
Transparency
Dusting Analysis
The Formula
Formulation
Stability
The raw material, a white powder, demonstrates stability for 24 months from its manufacturing date. Optimal storage conditions require a freezer environment at -20℃ to -15℃, protection from light, and an air-proof seal when not in use.
Synergies
- Palmitoyl Oligopeptide-78 (as part of X50 Skin barrier complex)
Safety
Safety Profile
Formal safety evaluations from regulatory bodies such as the CIR, SCCS, or FDA are currently absent for Palmitoyl Heptapeptide-27, leading to its classification as 'insufficient data.' Independent cosmetic databases also note a lack of comprehensively reviewed research on this ingredient.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Heptapeptide-27 demonstrates a promising mechanistic profile for bolstering skin barrier function and hydration; however, the lack of standalone clinical efficacy studies and comprehensive safety assessments warrants its classification as an ingredient with insufficient data for a definitive verdict.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources